Dr. Gonzalez-Martin on Rationale for Phase III PRIMA Trial in Advanced Ovarian Cancer

Video

Antonio Gonzalez-Martin, MD, discusses the rationale for the phase III PRIMA trial investigating niraparib (Zejula) as maintenance therapy for patients with platinum-sensitive advanced ovarian cancer.

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the rationale for the phase III PRIMA trial investigating niraparib (Zejula) as maintenance therapy for patients with platinum-sensitive advanced ovarian cancer.

The majority of patients with advanced ovarian cancer will relapse shortly after completing chemotherapy, says Gonzalez-Martin. Although there are maintenance therapy options, not all patients will benefit from them, he adds.

In the recurrent setting, niraparib has shown an improvement in progression-free survival (PFS) in platinum-sensitive patients regardless of BRCA status or homologous recombination deficiency (HRD) status. Therefore, PRIMA was designed to evaluate niraparib as frontline maintenance therapy in patients with high-risk of relapse.

In the overall population, the median progression-free survival (PFS) was 13.8 months in the niraparib arm compared with 8.2 months in the placebo arm (HR, 0.62; 95% CI, 0.50-0.76; P <.001). Notably, HRD-positive patients had a median PFS of 21.9 months with niraparib versus 10.4 months with placebo (HR, 0.43; 95% CI, 0.50-0.76; P <.001).

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,